SCHEDULING STATUS:

S2

PROPRIETARY NAME AND DOSAGE FORM:

GLENCET 5 TABLETS

COMPOSITION:

Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.

Excipients

Colloidal silicon dioxide (Aerosil 200), Lactose monohydrate, magnesium stearate , microcrystalline cellulose (Avicell pH102), opadry white (opadry Y-1-7000), purified water.

PHARMACOLOGICAL CLASSIFICATION:

A 5.7.1 Antihistaminics

PHARMACOLOGICAL ACTION:

Pharmacodynamics properties:

Levocetirizine, the (R) enantiomer of cetirizine, is a histamine H_1 receptor antagonist.

Pharmacokinetics

Levocetirizine is absorbed after oral administration with peak blood levels reached 0,9 hours after oral administration. Plasma levels are linearly related between 2,5 mg and 20 mg.

The extent of metabolism is less than 14 % of the dose. The plasma half-life is approximately 8 hours in adults. The main route of excretion is via urine, accounting for approximately 85 % of the dose. The extent of absorption is not reduced by food, although the rate is decreased.

Approximately 13 % is excreted in the faeces.

Levocetirizine is 90 % bound to human plasma proteins.

INDICATIONS:

GLENCET 5 is indicated for the relief of symptoms associated with the following allergic conditions in adults:

- Seasonal allergic rhinitis
- Perennial allergic rhinitis
- Chronic idiopathic urticaria

CONTRA-INDICATIONS:

- History of hypersensitivity to levocetirizine or to any of the ingredients of **GLENCET 5** or to any piperazine derivative.
- **GLENCET 5** is contra-indicated in children as safety and efficacy have not been demonstrated.
- End-stage renal impairment – creatinine clearance of less than 10ml / minute or patients receiving dialysis.
- Pregnancy and lactation (see "**PREGNANCY AND LACTATION**")

WARNINGS and SPECIAL PRECAUTIONS:

GLENCET 5 lacks significant sedative effects. However, in clinical trials the occurrence of somnolence, fatigue, and asthenia has been reported in some patients.

Concurrent use of **GLENCET 5** with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and impairment of central nervous system performance may occur.

GLENCET 5 should be used with caution in patients with renal impairment.

GLENCET 5 tablets contain 63,50 mg of lactose per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, should not take **GLENCET 5**.

Effects on Ability to Drive and use Machines

GLENCET 5 lacks significant sedative effects. Patients should, however be warned that a small number of individuals may experience sedation.
It is therefore advisable to determine individual response before driving or performing complicated tasks. This may be compounded by the simultaneous intake of alcohol or other central nervous system depressants.

INTERACTIONS

In sensitive patients the simultaneous use of **GLENCET 5** and alcohol or other central nervous system depressants may have effects on the central nervous system. It is advisable to avoid excessive alcohol consumption.

There are known interactions of **GLENCET 5** with other medicines through interactions with medicines metabolized by liver enzymes. Studies performed with racemic

cetirizine have shown no evidence of clinically relevant adverse interactions with ketoconazole erythromycin, azithromycin, cimetidine and pseudoephedrine.

Ritonavir increases the plasma concentration of cetirizine, increases the half-life and decreases the clearance. The disposition of ritonavir is not altered by concomitant administration.

Allergy skin tests are inhibited by antihistamines such as **GLENCET 5**. A wash-out period of 3 days is recommended before performing them.

Avoid excessive alcohol consumption.

PREGNANCY AND LACTATION:

GLENCET 5 is contra-indicated in lactating women since the active ingredient levocetirizine is excreted in breastmilk.

The safety of GLENCET 5 when administered concurrently in human pregnancy and lactation has not been established.

DOSAGE AND DIRECTIONS FOR USE:

Adults or children 12 years of age or older:

The daily recommended dose is one tablet daily.

The tablet must be swallowed with liquid and may be taken with or without food.

Patients with renal impairment

The total body clearance of levocetirizine is progressively reduced based on the severity of renal impairment. The dosing intervals must be individualized according to renal function.

Use the table below to adjust the dose as indicated.

The patient's creatine clearance can be estimated from the serum creatinine determination using the modified formula of Cockroft and Gault:

$$\text{CrCl (ml/min) male} = \frac{\text{Weight (kg)} \times (140\text{-age in years})}{(\text{plasma creatinine (micromol/litre)})}$$

CrCl (ml/min) female = 0,85 X male value

Dosages in patients with renal impairment		
Renal status	**Creatinine clearance (CL_{cr})**	**Dose**
Normal	≥ 80 ml/min	5 mg once daily
Mild impairment	50 to 79 ml/min	5 mg once daily
Moderate impairment	30 to 49 ml/min	5 mg every second day
Severe impairment	30 ml/min	5 mg every third day
End stage renal disease or receiving dialysis	< 10 ml/min	Contra-indicated

SIDE-EFFECTS:

The following side-effects have been reported. The risk of adverse reactions to **GLENCET 5** may be greater in patients with renal impairment.

Central Nervous system disorders:

Frequent: Headache, somnolence

Frequency unknown: Convulsions

Respiratory system disorders:

Frequent: Pharyngitis, naso-pharyngitis, dyspnoea

Gastro-intestinal system disorders:

Frequent: Dry mouth

Less frequent: Nausea and gastro-intestinal discomfort

General disorders:

Frequent: Fatigue, weight increase

Less frequent: Asthenia, malaise, anaphylaxis, myalgia

The following side effects have been reported, the frequency is unknown:

Skin and appendages disorders:

Frequency unknown: Hypersensitivity reactions including skin reactions such as rashes, fixed drug eruptions, urticaria, pruritus and angioedema may develop.

Psychiatric disorders:

Frequency unknown: Aggression, agitation, hallucination, depression

Eye disorders

Frequency unknown: Visual disturbances

Cardiac disorders

Frequency unknown: Palpitations, tachycardia

Hepatobiliary disorders:

Frequency unknown: Hepatitis

Investigations:

Frequency unknown: Abnormal liver function tests

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT

Drowsiness is an expected symptom of overdosage. Overdosage in children may initially produce agitation and restlessness followed by drowsiness.

There is no known specific antidote to levocetirizine. In the case of massive overdosage, gastric lavage should be performed with the usual supportive measures. Levocetitizine is not effectively removed by haemodialysis.

IDENTIFICATION:

White oval film coated biconvex tablet, plain on one side, the other side has a break-line and the tablet is embossed with a G above and below the break-line.

PRESENTATION:

GLENCET 5 tablets are packed in blisters packs and are available in pack sizes of 7's, 10's and 30's.

7's is packed in Alu/Hard tempered aluminium foil blister packs

10's and 30's are packed in White opaque, PVC/PVDC/Aluminium foil blister packs.

The blister strips are packed into cardboard boxes.

STORAGE INSTRUCTIONS:

Store at or below 25 °C. Protect from moisture.

Keep out of reach of children.

Keep the blister pack in the carton until required for use.

REGISTRATION NUMBER:

A 44/5.7.1/0843

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:

Activo Health (Pty) Ltd

Block B, Arena Office Park

272 West Avenue, Centurion

0157

DATE OF PUBLICATION OF THIS PACKAGE INSERT:

1 November 2017